Indian Journal of Ophthalmology (Jan 2012)

Change in macular thickness in a case of refractory diabetic macular edema with dexamethasone intravitreal implant in comparison to intravitreal bevacizumab: A case report

  • Ashish Sharma,
  • Rangasamy J Madhusudhan,
  • Vidhya Nadahalli,
  • Shreekant A Damgude,
  • Selva K Sundaramoorthy

DOI
https://doi.org/10.4103/0301-4738.95884
Journal volume & issue
Vol. 60, no. 3
pp. 234 – 235

Abstract

Read online

We report on the significant improvement of central macular thickness in a case of clinically significant macular edema after dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex®; Allergan, Inc, Irvine, CA, USA). Patient presented to us with persistent clinically significant macular edema (CSME) in both eyes. Right eye received dexamethasone implant and left eye received two intravitreal bevacizumab injections 1.25 mg/0.05 mL (Avastin®; Genentech Inc., South San Francisco, CA, USA) with an interval of four weeks. After six weeks of follow-up, dexamethasone implant in the right eye showed normal macular thickness whereas persistent macular edema (ME) was found even after second intravitreal bevacizumab injection in the left eye.

Keywords